

## PAPER

[View Article Online](#)  
[View Journal](#) | [View Issue](#)Cite this: *Mater. Adv.*, 2022, **3**, 2858

## Poly(lactic-co-glycolic acid) encapsulated platinum nanoparticles for cancer treatment†

Aida López Ruiz,  Evaristo Villaseco Arribas and Kathleen McEnnis  \*

Metal nanoparticles have been of interest to the field of nanomedicine due to their potential for cancer treatment, diagnosis, and antimicrobial activity. Particularly, platinum nanoparticles (PtNPs) have been reported to have remarkable anticancer effects and low toxicity in healthy cells. In this paper, we propose a delivery system for PtNPs as a substitute for common chemotherapy treatment. The anticancer effect of PtNPs was tested against triple negative breast cancer (TNBC) showing no cell viability for most of the concentrations used, while not being toxic against fibroblasts. To improve accumulation at the tumor site, a delivery system based on poly(lactic-co-glycolic acid) (PLGA) particles was used. Encapsulation was achieved by nanoemulsion, resulting in 59% PLGA particles containing PtNPs, and 12.5% PtNPs by weight. To improve the circulation time and specificity of the system, the PLGA particle surface was modified. Passive targeting with poly(ethylene glycol) (PEG) and active targeting with an antibody (anti-EGFR) were used, obtaining two different sets of particles, Pt-PLGA-PEG and Pt-PLGA-PEG-EGFR. To evaluate both sets of particles, cell studies were carried out against TNBC. Cell experiments demonstrated that Pt-PLGA-PEG-EGFR particles were more effective as a cancer treatment than Pt-PLGA-PEG particles, however, free PtNPs were more effective than the encapsulated PtNPs. This was likely due to the time needed for PtNPs to release from PLGA, however, the amount of Pt internalized in the cells was greater with the Pt-PLGA-PEG-EGFR particles. These results suggest that the Pt NPs encapsulated in PLGA modified with a combination of PEG and EGFR targeting will provide the most effective therapy for future *in vivo* experiments. In summary, this study lays the groundwork for future cancer treatments based on PtNPs delivered with targeted PLGA particles.

Received 7th December 2021,  
Accepted 14th February 2022

DOI: 10.1039/d1ma01155c

[rsc.li/materials-advances](http://rsc.li/materials-advances)

## Introduction

Nanotechnology is a multidisciplinary field with numerous applications including cancer treatment and detection. Noble metal based nanoparticles, such as palladium, platinum, gold, and silver have been studied in the field of medicine and pharmaceuticals due to their therapeutic potential.<sup>1–7</sup> In particular, platinum nanoparticles (PtNPs) have been reported with promising anticancer results.<sup>8–14</sup> There is evidence of PtNPs' capacity to enter the cell and damage DNA by releasing platinum ions.<sup>15,16</sup> The toxicity of PtNPs needs to be further studied as there are conflicting reports on whether they are toxic for all cell types or just cancer cells.<sup>17–19</sup> For instance, PtNPs altered the heart rate in mice but did not produce a deadly toxicity.<sup>20</sup> Li *et al.* tested PtNPs with mice *in vivo* finding no toxicity by histological analysis on several organs, however, a large accumulation of PtNPs was observed in the liver, spleen and kidney.<sup>21</sup> The Food and Drug Administration (FDA), however, has concluded that

platinum in a zero oxidation state has the lowest toxicity compared to other oxidation states.<sup>22</sup> The low toxicity of PtNPs compared to common chemotherapeutic drugs like cisplatin is an advantage that needs to be further studied.

The toxicity of metallic nanoparticles when in contact with oxidizing agents from blood is a major limitation to their use in nanomedicine.<sup>19</sup> A drug delivery system, however, can decrease toxicity for the patient by directly supplying the drug to the target, resulting in less drug needed overall.<sup>23</sup> The usage of particles for drug delivery increases drug efficacy, specificity, tolerability, and therapeutic index.<sup>24,25</sup> Poly(lactic-co-glycolic acid) (PLGA) based systems are frequently employed as delivery vehicles due to their biodegradability, biocompatibility, and minimal toxicity.<sup>26–31</sup> There are reports where PLGA particles have been used with traditional drugs for cancer treatment, such as docetaxel and paclitaxel.<sup>25,26,32</sup> Nonetheless, the toxicity of these drugs in off-target accumulation areas, such as the liver, typically prevents the application of these particles in clinical trials.<sup>33–35</sup> Delivering PtNPs with targeted PLGA particles, however, is a novel, synergistic approach to minimize toxicity to healthy cells.

Nanoparticles that circulate in the bloodstream are recognized by proteins and these proteins attach to the surface

Department of Chemical and Materials Engineering, New Jersey Institute of Technology, 161 Warren St, Newark, NJ, 07102-1982, USA.

E-mail: [mcennis@njit.edu](mailto:mcennis@njit.edu)

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ma01155c




Fig. 1 Schematic representation of PtNPs encapsulation with PLGA and surface modifications.

forming a nanoparticle–protein complex (protein corona) that triggers the phagocytic system recognition and removal from the bloodstream.<sup>36,37</sup> Surface modification of the particles with polymers such as polyethylene glycol (PEG) have been found to enhance the circulation life-time of the particles.<sup>38</sup> Surface modifications with PEG are a commonly used procedure to enhance the properties of drug delivery systems through passive targeting. Additionally, ligands of specific biomarkers, monoclonal antibodies, peptides, or aptamers can be used to provide the most effective targeted therapy through active targeting.<sup>35,39–41</sup> In the current project, the anticancer activity of PtNPs was tested against triple negative breast cancer (TNBC). Triple negative breast cancer is defined by the lack of overexpression of the three common receptors used to classify breast cancer.<sup>42</sup> Therefore, there are very few available targets and no targeted therapies currently available.<sup>43–45</sup> Epidermal growth factor (EGF) is a receptor that promotes cell proliferation migration and angiogenesis (development of new blood vessels)<sup>46</sup> and is overexpressed in many tumors including breast cancer.<sup>47</sup> Therefore, many strategies based on antibodies have been studied to block EGFR.<sup>46</sup> The anti-EGFR monoclonal antibody, Cetuximab, has shown promising results for targeting metastatic TNBC.<sup>48,49</sup>

In the present study, we synthesized PtNPs to use as an anticancer treatment with no toxicity for healthy cells. The PtNPs were encapsulated with PLGA and surface modifications were performed to achieve increased cellular uptake (Fig. 1). This study adds further evidence of the effectiveness of PtNPs as a possible cancer treatment. Additionally, the encapsulation of PtNPs in a delivery system like PLGA and further surface modifications has not been investigated before. The cytotoxicity of PtNPs was tested with TNBC cells and fibroblasts showing that the PtNPs were highly effective against cancer cells with limited toxicity to the healthy fibroblast cells. Cisplatin, a common chemotherapeutic drug that contains a central platinum ion, was used as a control group that showed toxicity at all concentrations tested for both kinds of cells. PtNPs were encapsulated with PLGA by nanoemulsion, and then surface modifications were performed to enhance the effect of PtNPs on the targeted cells by adding PEG and an anti-EGFR ligand. Finally, cytotoxicity with TNBC of actively and passively targeted

particles was compared, demonstrating increased cell death by particles conjugated with the antibody. This research lays the groundwork for an alternative cancer treatment for triple negative breast cancer with low toxicity to healthy cells.

## Experimental

### Materials

Hexadecyltrimethylammonium bromide (CTab), poly(ethylene glycol) 2-aminoethyl ether biotin (PEG–biotin) (Mn 3400), dichloromethane, *N,N*-dimethylformamide, TWEEN<sup>®</sup> 20, poly(vinyl alcohol) (PVA), chloroform, Brij<sup>®</sup> 58, L-ascorbic acid, potassium tetrachloroplatinate(II) and acetonitrile anhydrous 99.8% were purchased from Sigma Aldrich. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide–HCl (EDC), sulfo-NHS and neutravidin biotin binding protein were purchased from Thermo Scientific. PLGA (Purasorb 5002A) with a 50 : 50 ratio of glycolic acid : lactic acid and 5000 g mol<sup>−1</sup> molecular weight was provided by Corbin Purac. Amino-poly(ethylene glycol) (Mw 5000 Da) was purchased from Nanocs. Rabbit mAb Cetuximab Biotin and Goat anti-Rabbit IgG (H + L) secondary [Dylight 488] were purchased from Novus Biologicals. Cisplatin CRS was purchased from European Pharmacopeia Reference Standard. Dulbecco's modification of Eagle's medium (DMEM) was purchased from Corning. Fetal bovine serum (FBS), antibiotic–antimycotic, and phosphate buffered saline (PBS) were purchased from Gibco. Fibroblast Growth Basal Medium (FBM) was purchased from Lonza Corp. CellTiter 96<sup>®</sup> Aqueous One Solution Cell Proliferation assays (MTS) were purchased from Promega. Live/dead cell imaging kit was purchased from Invitrogen. Two cell lines were used, triple negative breast cancer (TNBC) (MDA-MB-231) purchased from American Type Culture Collection (ATCC) and human ventricular cardiac fibroblasts (NHCF-V) from Lonza Corp.

### Methods

**Preparation of platinum nanoparticles.** Platinum nanoparticles were prepared by following the methodology by Shim *et al.*<sup>50</sup> First K<sub>2</sub>PtCl<sub>4</sub> solution (5 mL, 20 mM) was mixed with Brij58 solution (1 mL, 0.044 M) and sonicated for 10 min using a bath sonicator (Branson 2800). Then L-ascorbic acid solution (5 mL, 0.04 M) was mixed with the previous solution and sonicated for 45 min. After the reaction, the precipitate was collected by centrifuging 3 times.

**Characterization of platinum nanoparticles.** Size and shape of PtNPs were characterized by FEI Tecnai G2 Spirit Twin Transmission Electron Microscopy (TEM) at an operating voltage of 120 kV. For the sample preparation, nanoparticles were dried on 300-mesh copper-coated grids with a carbon film purchased from Electron Microscopy Science. X-ray diffraction (Philips, Empyrean) was used to characterize the crystallinity of Pt NPs, with a start position of 30°, an end position of 90°, and a scan step time of 997 seconds.

**Encapsulation of platinum nanoparticles by nanoemulsion.** The nanoemulsion technique is based, with some modifications, on the



work from Fatima *et al.*<sup>51</sup> The encapsulation was performed by double emulsion. PVA (0.5% w/v) and varying amounts of PtNPs were added to ultrapure water (200  $\mu$ L) to create the first aqueous phase. Preparation of the organic phase was carried out by dissolving PLGA (10 mg) in dichloromethane (0.4 mL). Then, the first aqueous phase was added dropwise into the organic phase and emulsified for 1 min with tip sonication at 25 W and 30% amplitude using a QSonica model CL-334 sonicator. Next, the 1st emulsion was added dropwise into a solution of PVA (1% w/v, 1.6 mL). The final solution was emulsified again by sonicating at 25 W and 30% amplitude for 2 min (2nd emulsion). Finally, the 2nd emulsion was stirred overnight at room temperature to remove the solvent. The particles were recovered by centrifuging and washing with ultrapure water 3 times.

**Characterization of the encapsulation of platinum nanoparticles with PLGA particles.** To determine the encapsulation of platinum nanoparticles with PLGA particles and the resulting morphology of the particles, the samples were analyzed with an FEI Tecnai G2 Spirit Twin Transmission Electron Microscope (TEM) at an operating voltage of 120 kV. Samples were stained with uranyl acetate to increase the contrast of the polymer. To determine the weight percentage loading of PtNPs with PLGA, thermogravimetric analysis (TGA) was carried out on a PerkinElmer 8000 TGA in the range of 25 °C to 600 °C with a 10 °C min<sup>-1</sup> heating rate. To determine the percentage of PLGA particles with PtNPs encapsulated in them, image analysis of TEM images using ImageJ was performed. For size distribution analysis, nanoparticle tracking analysis (NTA) was performed.

**Surface modifications.** Surface modifications were performed to attach poly(ethylene glycol) (PEG) and the antibody Cetuximab to the PLGA particles.

**PEGylation.** The previously freeze-dried particles were redispersed in 1 mL of MES buffer solution containing 0.4 mg EDC. The solution was left reacting for 10 min at room temperature on a rotator. After the particles reacted with EDC, 20  $\mu$ L of a solution of 1.1 mg sulfo-NHS with 40  $\mu$ L MES was added to the particle solution, vortexed, and left reacting on the rotator for 10–15 min at room temperature. The particles were centrifuged at 22 136 RCF for 1 h, then the supernatant was removed and 1 mL of PBS was added and tip sonicated. Different amounts of PEG (5 kDa) and PEG-Biotin (3 kDa) were added to the solution and left reacting for 2 h on the rotator at room temperature. Finally, to remove the excess of PEG, unreacted particles were washed three times by centrifuging at 22 136 RCF for 1 h and replacing the supernatant with PBS.

**Antibody attachment.** The biotin labeled antibody was attached to the particles through conjugation with neutravidin. A solution of 10 mg neutravidin in 0.5 mL 0.1% Tween PBS was added into a well on a 4-well plate with a stir bar. The particles previously tip sonicated were added dropwise into the neutravidin solution and left reacting for 3 h at room temperature. After the particles reacted, the solution was centrifuged at 22 136 RCF for 1 h and washed three times with PBS, to remove

the unreacted neutravidin. The particles were then tip sonicated and 13.3  $\mu$ L of biotin-antibody was added to the tube and left reacting for 3 h on a rotator at room temperature. Particles were then centrifuged at 22 136 RCF for 1 h and washed three times in PBS, to remove the unreacted antibody.

**Characterization of PEG attachment.** To characterize the PEGylation of the particles, zeta potential of the particles was studied. A solution of 1 mL of each of the particle samples with a minimum concentration of particles of 10<sup>9</sup> particles mL<sup>-1</sup> was used. As the surface of the PLGA particles contains carboxylic acid groups, the zeta potential of unmodified PLGA is negative. Upon modification with neutral PEG, the zeta potential increases. By measuring zeta potential with a Zetasizer Nano ZS, Malvern Instrument, it was possible to compare PLGA particles with and without PEG to confirm the attachment.

**Antibody attachment characterization.** To determine if the antibody was successfully conjugated with the nanoparticles, a fluorescently labeled complementary secondary antibody was used; 10  $\mu$ L of secondary antibody was added into the particle solution and left to react for 3 h on a rotator covered with aluminum foil. After the reaction was completed, the solution was centrifuged at 22 136 RCF for 1 h and washed with PBS three times, to remove the unreacted secondary antibody. To characterize the attachment of the secondary antibody, NTA was used with a 488 nm laser, in fluorescent mode with a 500 nm filter to visually confirm the signal from the fluorescently labeled secondary antibody.

**Cell viability.** To determine cytotoxicity of the nanoparticles and cisplatin with cells, MTS assays were performed with two different cell lines: triple negative breast cancer (TNBC) cell line MDA-MB-231 purchased from ATCC and human ventricular cardiac fibroblasts (NHCF-V) from Lonza Corp. The cells were cultured with Dulbecco's Modified Eagle's Medium (DMEM), complemented with 10% fetal bovine serum (FBS) and a 1% antibiotic-antimycotic solution. Incubation was carried out in a 75 mL flask at 37 °C. Once cells reached 80% confluency, they were detached from the flask using trypsin (0.05% solution) for 5 min. Then, cells were collected by centrifuging at 117 RCF for 5 min.

CellTiter 96<sup>®</sup> Aqueous One Solution Cell Proliferation assays (MTS) were performed for 1, 3, and 5 days. Cells were cultured for 24 hours at 37 °C (50 000 cells mL<sup>-1</sup>) in a 96-well plate. After incubation, the media was replaced with different concentrations of treatment and then incubated for 1, 3, or 5 days without replacing the media. After incubating for 1, 3, or 5 days, cell viability was then determined by removing the media and substituting with the MTS solution, followed by incubation for 4 hours at 37 °C. Cell viability was quantified by measuring absorbance at 490 nm using a spectrophotometer (SpectraMax Paradigm, Molecular Devices). All experiments were performed in triplicate for each time point and on three different days.

**Live/dead.** Cell viability live/dead studies were performed as a qualitative measurement using confocal microscopy (TCS SP8 MP, Leica). Cells (100 000 cells mL<sup>-1</sup>) were cultured on a 6-well



plate with glass slides. After a day of incubation, media was removed, and a solution of media and treatment was added to the cells. Cisplatin ( $50 \mu\text{g mL}^{-1}$ ), PtNPs ( $200 \mu\text{g mL}^{-1}$ ), Pt-PLGA-PEG ( $100 \mu\text{g mL}^{-1}$ ) or Pt-PLGA-PEG-EGFR ( $100 \mu\text{g mL}^{-1}$ ) was used. After the required days of treatment (1, 3, and 5 days), cells were washed with PBS. Then different fluorescent dyes (1.25  $\mu\text{L}$  of each), calcein-AM, and ethidium homodimer-1 from the live/dead cell imaging kit were added to a PBS solution (1 mL). The plate was kept in dark conditions for 15 min. Finally, the glass slides were removed from the plate and placed on a microscope slide for imaging.

**Cellular uptake.** Cellular uptake experiments were performed to determine the amount of Pt internalized by TNBC cells (MDA-MB-231). For these experiments, cells were incubated with  $100 \mu\text{g mL}^{-1}$  of PtNPs, Pt-PLGA-PEG or Pt-PLGA-PEG-EGFR, for 1, 3, and 5 days. After the incubation period of the cells with the particles, the supernatant was removed, the cells were detached from the plate using a solution of trypsin. Then, the cells were lysed and sent for analysis at Rutgers, The State University of New Jersey.

Samples (50  $\mu\text{L}$ ) were mixed with concentrated double-distilled nitric acid (DD  $\text{HNO}_3$ ; 200  $\mu\text{L}$ ) in metal-free polypropylene centrifuge tubes, sonicated for 60 min, then digested using a CEM microwave system (CEM, Matthews, NC) in 5 minute intervals for a total of 30 min at 300 W (75% power). Samples were diluted with MilliQ water to produce an acid concentration of 5%  $\text{HNO}_3$  for analysis *via* ICP-MS (dilution factor = 80 $\times$ ).

Pt concentrations in digested samples were quantified using a Nu AttoM Inductively Coupled Plasma Mass Spectrometer (ICP-MS), maintained in the Chemical Analysis Facility Core at the Environmental and Occupational Health Sciences Institute of Rutgers University, and operated at low resolution (300). The operating conditions were as follows: RF power of 1550 W, carrier gas flow of  $1.00 \text{ L min}^{-1}$  Ar, and nebulizer gas flow of  $\sim 34 \text{ psi}$  Ar. Three replicates at masses 194 Pt, 195 Pt, and 196 Pt were measured in deflector jump mode with 1.5 ms peak dwell time, 300 sweeps, and 10 cycles, and averaged (RSD < 5%). Calibration standards were prepared daily with Pt concentrations ranging from 0.001–1 ppb, in 5%  $\text{HNO}_3$ , with an instrument detection limit < 0.005 ppb and a method detection limit of 0.4–0.8 ppb. Sample concentrations were determined using a linear regression through seven standards, with a correlation coefficient > 0.999 for all runs. Quality control standard (SPEX CertiPrep Multi-element Solution 3) was repeatedly measured after every sixth sample to account for instrument drift and reproduced with RSD < 4% ( $n = 6$ –11 dependent on batch size). Four (4) procedural blanks were prepared alongside samples to account for acid background contribution and/or contamination during sample preparation; all blanks measured below the detection limit (< 0.005 ppb). Four (4) matrix matched standards were prepared by spiking Pt into control cell media (0.25 ppb) and measured to account for matrix effects (98–103% recovery). The percent uptake of Pt was determined by comparing the concentration of Pt found in the cells to the concentration of Pt in the original Pt solution incubated with the cells.




Fig. 2 (A) TEM images of PtNPs, (B) Size distribution, (C) X-ray diffraction of PtNPs.

### Statistical analysis

Data were analyzed by a one-way ANOVA, followed by Tukey's post-test. Data were considered statistically significant when the  $p$ -values were < 0.05, and  $p$ -values > 0.05 were considered not statistically significant.

## Results and discussion

### Evaluation of platinum nanoparticles

In recent years platinum nanoparticles have shown promising results as an anticancer agent.<sup>52</sup> Several studies have found that PtNPs of 50 nm have an anticancer effect, however other studies showed that PtNPs of 5 nm and 20 nm had no anticancer effect.<sup>10,21,50,53,54</sup> Therefore, in the present study, platinum nanoparticles were synthesized by chemical reduction following the methodology of Shim *et al.*, to achieve a size of 50 nm.<sup>50</sup> The size, shape, and crystallinity of the PtNPs were determined by TEM and X-ray diffraction (XRD). By image analysis, a dendrimer shape was observed with a size distribution of  $45 \text{ nm} \pm 10 \text{ nm}$ , consistent with the size and shape previously reported<sup>10,21,50,55</sup> (Fig. 2). Crystallinity was determined by using XRD (Fig. 2), showing peaks corresponding to the (111), (200), (220), (311), and (222) planes, in agreement with the data reported by Shim *et al.*<sup>50</sup>

To assess the effectiveness of PtNPs as an anticancer agent and the toxicity for healthy cells, two different cell lines were used: MDA-MB-231 (TNBC) and NHCF-V (fibroblasts). Cisplatin was used as a control representing a current FDA approved treatment for breast cancer. Cell viability studies were performed using an MTS assay with different concentrations of PtNPs and cisplatin for 1, 3, and 5 days for both cell lines. Through these experiments, the inhibitory concentration of treatment needed ( $\text{IC}_{50}$ ) was calculated.

PtNPs incubated with TNBC show a dose dependent anticancer effect. Cell viability declined visibly by using PtNPs for






Fig. 3 Cell viability for PtNPs using (A) TNBC and, (B) fibroblasts, for 1, 3, and 5 days with different concentrations of treatment. Results are expressed as mean + SD (\*\*\* $p < 0.001$ ). Therefore, PtNPs are effective against TNBC but do not affect fibroblasts.

all concentrations tested and showed statistically significant differences compared to the untreated control cells. By increasing PtNP concentrations, cell viability decreased (Fig. 3A). At the lowest concentration tested ( $10 \mu\text{g mL}^{-1}$  PtNPs) cell viability was 80% whereas for the highest concentration ( $200 \mu\text{g mL}^{-1}$  PtNPs) cell viability decreased to 2% at 5 days incubation period. A time-dependent effect was also observed, with longer treatment with PtNPs resulting in less viability.

Cytotoxicity with healthy cells (fibroblasts) was tested at the same concentrations used for TNBC treatments (Fig. 3B). An initial decrease in the cell viability was observed after 1 day of treatment, however, after a period of 3 and 5 days, the cell viability increased until there were no statistically significant differences in the cell viability between the untreated control and the use of PtNP treatment after 5 days at all concentrations.

Cisplatin was used as a comparison with a common chemotherapeutic drug. Although cisplatin is more effective than PtNPs at treating TNBC (Fig. 4A) its toxicity to healthy cells constitutes one of its main drawbacks. Lower concentrations of cisplatin were further tested against TNBC to assess a more accurate minimum inhibitory concentration (Fig. S1, ESI†). As shown in Fig. 4B, cisplatin did not display selectivity and showed high toxicity for both healthy and cancer cells.

To assess the minimum concentration to decrease cell viability by half,  $\text{IC}_{50}$  was calculated (Fig. S2, ESI†). When using PtNPs against TNBC, the concentration needed decreased from

$44 \mu\text{g mL}^{-1}$  at 1 day incubation period to  $21 \mu\text{g mL}^{-1}$  at 5 days incubation period, confirming the time-dependent effect (Table 1). Although cisplatin is more effective than PtNPs at treating TNBC, achieving an  $\text{IC}_{50}$  of less than  $1 \mu\text{g mL}^{-1}$  for any time point (Table 1), a similar  $\text{IC}_{50}$  was obtained for fibroblasts. However, for PtNPs it was not possible to calculate  $\text{IC}_{50}$  against fibroblasts since they showed no toxicity.

MTS assays used for this cell viability data are a measure of cell metabolism. If the number of cells present is low, then the intensity of the signal will also be low, leading to the assumption of cell death. The initial decrease in cell viability using PtNPs followed by an increase is likely associated with an inhibition of cell growth caused by PtNPs, as opposed to cell death. To confirm this hypothesis, live/dead experiments were performed. These experiments represent a qualitative measure of cell viability. Cells will appear green if they are alive and red otherwise. To evaluate both cell viability and confluence, the highest concentrations of PtNPs ( $200 \mu\text{g mL}^{-1}$ ) and cisplatin ( $50 \mu\text{g mL}^{-1}$ ) were compared with the control group.

With this experiment, it was confirmed that the PtNPs were not toxic to fibroblasts, and the confluence of fibroblasts did increase after 3 days of culture (Fig. 5). The absence of red cells when using PtNPs, and the increasing number of cells by day 3 showed that cells are growing slower but not dying. By day 5 there was no difference between the use of PtNPs and the control group. The mechanism of action of PtNPs has been of






Fig. 4 Cell viability for cisplatin using (A) TNBC and, (B) fibroblasts, for 1, 3, and 5 days with different concentrations of treatment. Results are expressed as mean + SD (\*\*\*)  $p < 0.001$ . Therefore, cisplatin was toxic for both cell lines.

**Table 1**  $IC_{50}$  for PtNPs with TNBC, cisplatin with TNBC, and cisplatin with fibroblasts for 1, 3 and, 5 days. PtNPs showed no toxicity toward fibroblasts, so an  $IC_{50}$  could not be calculated

|        | $IC_{50} \mu g mL^{-1}$ |                   |                |                       |
|--------|-------------------------|-------------------|----------------|-----------------------|
|        | PtNPs–TNBC              | PtNPs–fibroblasts | Cisplatin–TNBC | Cisplatin–fibroblasts |
| 1 Day  | 44                      | NA                | 0.4            | 18                    |
| 3 Days | 14                      | NA                | 0.3            | 3                     |
| 5 Days | 22                      | NA                | 0.2            | 3                     |

interest for several years, however, there are conflicting reports suggesting the mechanism is related to ROS production or the release of platinum ions. It has been demonstrated that PtNPs increase the level of ROS produced inside the cell, damaging the DNA of the cells, stopping replication, and causing apoptosis.<sup>56</sup> Furthermore, Bendale *et al.* tested PtNPs against red blood cells (PBMCS) finding no toxicity for healthy cells while causing toxicity for cancer cells (A375).<sup>13</sup> They concluded that platinum enters the nucleus of the cell, causing fragmentation of the DNA. However, even though PtNPs are generally considered to have low toxicity, the harmless effect against cardiac fibroblast has never been found before. Moreover, the selectivity of PtNPs has not been studied. We hypothesize that the selectivity of PtNPs can be associated with the oxidative state of PtNPs, which may be altered by the more acidic pH of the cancer environment.<sup>57</sup> Cisplatin, however, manifests high

toxicity for fibroblasts corroborating the MTS results. Based on the obtained results, PtNPs were further investigated in combination with a PLGA particle delivery system.

### Encapsulation

Systemic administration of drugs has many drawbacks for patients. Delivery systems can result in a larger dose of the drug to the target, increasing the pharmacokinetics of the material.<sup>58</sup> Due to the drug dosage limitation of PtNPs and potential accumulation in the liver, spleen, and kidneys, the use of a delivery system was studied. PLGA is an FDA approved material for drug delivery with no toxicity (Fig. S3, ESI†).<sup>26,28,59</sup> Due to its biocompatibility, PLGA was chosen as a preferred material for the preparation of a delivery system for PtNPs. Different techniques were used to encapsulate PtNPs including nanoprecipitation, and electrohydrodynamic (EHD) co-jetting (Fig. S4 and S5, ESI†). Nanoprecipitation was tested with two different organic solvents, acetone and acetonitrile, but the hydrophilic nature of PtNPs led to large aggregates when dispersed with an organic solvent (Fig. S4, ESI†). By EHD, different concentrations of CTab were tested to modulate PLGA sizes, however, results included large aggregates of PtNPs or PLGA particles that were too small (Fig. S5, ESI†). Therefore, the highest encapsulation rate was achieved by nanoemulsion.

Emulsification has been widely studied for the synthesis of polymeric particles. Specifically, the water/oil/water (W/O/W) double emulsion has been used to encapsulate hydrophilic






Fig. 5 Live/dead assay with fibroblasts (NHCF-V), an initial image (day 0) before adding the treatment, and then using PtNPs ( $200 \mu\text{g mL}^{-1}$ ) and cisplatin ( $50 \mu\text{g mL}^{-1}$ ) after 1, 3, and 5 days of treatment. PtNPs appear to slow the growth of fibroblasts without killing them, but growth began to recover at 3 days incubation.

drugs.<sup>60,61</sup> Specifically, nanoemulsion has been used to encapsulate cisplatin inside PLGA particles.<sup>62,63</sup> For the first emulsion, a water phase containing the PtNPs was introduced into the organic phase with PLGA dissolved. Afterward, the mixture was emulsified by probe sonication. This step forms water droplets containing PtNPs inside the organic phase. Then, the first emulsion is introduced dropwise into a second water solution with surfactant and probe sonicated to form a second emulsion that will contain PtNPs encapsulated in PLGA particles (Fig. 6A). Three different formulations were tested with varying amounts of PtNPs. The first formulation used  $0.01 \text{ mg } \mu\text{L}^{-1}$  of PtNPs in aqueous solution, and TEM images showed that most of the PLGA particles were empty (Fig. 6B). Therefore, higher concentrations of PtNPs,  $0.015 \text{ mg } \mu\text{L}^{-1}$  and  $0.02 \text{ mg } \mu\text{L}^{-1}$ , were tested in an attempt to increase the loading. For the greatest concentration used ( $0.02 \text{ mg } \mu\text{L}^{-1}$ ), the PtNPs aggregated, decreasing encapsulation efficiency (Fig. 6C). However, with  $0.015 \text{ mg } \mu\text{L}^{-1}$  of PtNPs in aqueous solution, the encapsulation of PtNPs was successfully achieved with few empty PLGA particles. TEM analysis showed PLGA particles




Fig. 6 Nanoemulsion encapsulation of PtNPs with PLGA particles. (A) Schematic illustration of the double emulsion process to form particles. TEM images of double emulsion encapsulation with three different concentrations of PtNPs (B)  $0.01 \text{ mg } \mu\text{L}^{-1}$  (C)  $0.02 \text{ mg } \mu\text{L}^{-1}$  (D)  $0.015 \text{ mg } \mu\text{L}^{-1}$ . Concentration tested on (D)  $0.015 \text{ mg } \mu\text{L}^{-1}$  resulted in the highest encapsulation rate of PtNPs, and therefore was used for further experiments.

with many PtNPs encapsulated, as well as some single PtNPs with a thin PLGA coating (Fig. 6D).

After confirming the encapsulation of PtNPs with PLGA particles, further characterization was performed for the  $0.015 \text{ mg } \mu\text{L}^{-1}$  PtNPs formulation. By image analysis of the TEM images (70 images) of 3 batches of this formulation, 59% of the PLGA particles (218 out of 436 particles) were found to contain PtNPs. These results are comparable to other formulations where cisplatin is encapsulated with PLGA, achieving an encapsulation efficiency of 60%.<sup>62</sup> Furthermore, thermogravimetric analysis (TGA) of the three batches of the  $0.015 \text{ mg } \mu\text{L}^{-1}$  PtNPs formulation resulted in a 12.5 weight% loading of PtNPs in PLGA (Fig. 7A). Size analysis using nanoparticle tracking analysis (NTA) measurements reported a mode size of  $140 \text{ nm} \pm 2.7 \text{ nm}$  (Fig. 7B).





Fig. 7 (A) Thermogravimetric analysis of  $0.015 \text{ mg } \mu\text{L}^{-1}$  PtNPs with PLGA particles by nanoemulsion shows 12.5% weight percent loading of PtNPs. Performed 3 times with 3 different batches. (B) Size distribution by nanoparticle tracking analysis of  $0.015 \text{ mg } \mu\text{L}^{-1}$  PtNPs with PLGA particles by nanoemulsion. Shows a mode size of 140 nm.




**Fig. 8** Schematic representation of surface modifications performed on PLGA particles. Pegylated particles (Pt-PLGA-PEG) and antibody modified particles (Pt-PLGA-PEG-EGFR). B stands for biotin, N for neutravidin and Cetuximab is the commercial name of the monoclonal anti-EGFR antibody.

### Surface modifications

The addition of passive and active targeting ligands can provide a more effective treatment for TNBC, therefore two different surface modifications were performed (Fig. 8). PEGylation has been reported as an effective way to prevent protein adsorption onto the surface of the nanoparticles by creating a hydration layer,<sup>64</sup> while the addition of an antibody gives specificity to the system to target a specific cancer cell type.<sup>46</sup> The overexpression of EGFR on TNBC cells makes it a promising target for drug delivery systems.<sup>46,47</sup> Therefore to compare the effect of a

targeted delivery system with a passively targeted system, two groups of particles were synthesized, PEGylated particles (Pt-PLGA-PEG) and antibody attached particles (Pt-PLGA-PEG-EGFR). The PEGylated particles were decorated with 5 kDa PEG, while the antibody particles were decorated with 5 kDa PEG and 3 kDa PEG-biotin used to attach the EGFR by bioaffinity. Zeta potential and NMR were used to determine PEGylation of the nanoparticles (Fig. S6, ESI†). The attachment of PEG was confirmed by an increase of the zeta potential from  $-34 \pm 1.04$  mV for bare PLGA particles to  $-19 \pm 1.06$  mV for the decorated particles. The presence of the peak at 3.62 ppm associated with  $\text{CH}_2$  group in PEG also confirmed the presence of PEG on the particles. NTA was used to determine the size and the attachment of the EGFR to the particles (Fig. S6, ESI†). By using a secondary fluorescent antibody, the attachment of the EGFR was confirmed through visualization of the fluorescent signal. The mode size was  $188.0 \pm 6.3$  nm for Pt-PLGA-PEG and  $211.6 \pm 15.2$  nm for Pt-PLGA-PEG-EGFR (Fig. S6, ESI†).

Cell viability experiments were performed with both sets of particles against TNBC cells. For these studies, 4 different concentrations of particles were tested, 10, 100, 200, and  $400 \mu\text{g mL}^{-1}$ , over 1, 3, and 5 days (Fig. 9). Both sets of particles showed statistically significant results between the control group and the highest concentrations of particles on day 1 and day 3. Therefore, both sets of particles showed a therapeutic effect against TNBC. However, TNBC cells were more affected by the particles delivered with the targeting antibody, showing lower cell viability for all the concentrations when compared with Pt-PLGA-PEG. To further prove that the targeting with EGFR was more effective, the  $\text{IC}_{50}$  (Fig. S7, ESI†) for



**Fig. 9** Cell viability with TNBC using (A) Pt-PLGA-PEG particles and, (B) Pt-PLGA-PEG-EGFR, for 1, 3, and 5 days with different concentrations of treatment. Results are expressed as mean + SD ( $***p < 0.001$ ). The attachment of an antibody increases cancer cell death.


**Table 2** IC<sub>50</sub> for Pt-PLGA-PEG and Pt-PLGA-PEG-EGFR with TNBC for 1, 3 and 5 days. Particles targeted with an EGFR antibody showed a lower IC<sub>50</sub> than PEGylated particles

|        | IC <sub>50</sub> $\mu\text{g mL}^{-1}$ |                               |
|--------|----------------------------------------|-------------------------------|
|        | Pt-PLGA-PEG against TNBC               | Pt-PLGA-PEG-EGFR against TNBC |
| 1 Day  | 261                                    | 109                           |
| 3 Days | 298                                    | 239                           |
| 5 Days | 328                                    | 250                           |


both sets of particles was calculated. Table 2 shows that the minimum concentration to decrease cell viability by half was higher when using Pt-PLGA-PEG than for Pt-PLGA-PEG-EGFR. Therefore, the targeting of the particles with an antibody provides the most effective treatment against TNBC. However, if we compare IC<sub>50</sub> values in Table 1 for PtNPs with TNBC and Table 2 for Pt-PLGA-PEG-EGFR with TNBC, the concentration of PtNPs needed to achieve the IC<sub>50</sub> (14–44  $\mu\text{g mL}^{-1}$ ) is lower for bare PtNPs than for Pt-PLGA-PEG-EGFR (109–250  $\mu\text{g mL}^{-1}$ ). This phenomenon is likely associated with the release of PtNPs from the PLGA particles. The encapsulation of PtNPs increases the time to be released, increasing the concentration of

particles needed to achieve the same effectivity as free PtNPs. Moreover, size of encapsulated PtNPs is significantly increased compared with free PtNPs. The optimum size for particle internalization is around 50 nm, and cellular uptake decreases with increasing particle size.<sup>65</sup> Particles of 30–50 nm are internalized *via* receptor-mediated endocytosis, however, particles with a size smaller than 200 nm are internalized *via* caveolae-mediated endocytosis.<sup>66</sup> Therefore, particle size is generally a key factor for cellular uptake. However, the cellular uptake data in this study (Fig. 11) suggests that the size increase does not affect internalization. Hence, release time of PtNPs is the most likely phenomenon associated to the need to increase concentration of encapsulated PtNPs compared to free PtNPs.

To further compare passively targeted and actively targeted particles, live/dead experiments with Pt-PLGA-PEG and Pt-PLGA-PEG-EGFR against TNBC were performed, with a concentration of 100  $\mu\text{g mL}^{-1}$  over 1, 3, and 5 days (Fig. 10). In Fig. 10, as time increases the cells incubated with either type of particles show more cell death (red cells) compared to the control, which appears healthy (green cells). Moreover, the cells incubated with the actively targeted particles (Pt-PLGA-PEG-EGFR) have more cell death than the passively targeted particles (Pt-PLGA-PEG), agreeing with the IC<sub>50</sub> values in Table 2. These experiments were performed with a concentration of 100  $\mu\text{g mL}^{-1}$  for both types of particles, showing that even a lower concentration of particles can achieve a significant change in cell viability. In addition to providing information about cell viability, live/dead experiments can also indicate when the cells are affected by the treatment but not dead yet. In Fig. 10, when incubated with both sets of particles, the cells show a yellow color, indicating stress, in comparison to the control group composed of healthy cells (green). Longer incubation periods led to more cell death, observed by the shift in cell color (from yellow to red). This was a confirmation of the need for longer exposure times of the particles with the cells, to



**Fig. 10** Live/dead assay with TNBC (MBA-MD-231), an initial image (day 0) before adding the treatment, and then incubation with Pt-PLGA-PEG (100  $\mu\text{g mL}^{-1}$ ) and Pt-PLGA-PEG-EGFR (100  $\mu\text{g mL}^{-1}$ ) after 1, 3, and 5 days of treatment.



**Fig. 11** Cellular uptake of Pt with Pt NPs, Pt-PLGA-PEG and Pt-PLGA-PEG-EGFR against TNBC for 1, 3 and 5 days. Results are expressed as mean + SD (\*\*\* $p < 0.001$ ).



allow for the release of the particles and internalization by the cells.

Surface modifications on particles with active targeting should increase the internalization of the particles by the cells. Therefore, to test particle internalization, cellular uptake experiments were performed based on ICP-MS analysis. Fig. 11 compares the cellular uptake of bare PtNPs and the two combinations of surface modifications, Pt-PLGA-PEG and Pt-PLGA-PEG-EGFR with TNBC cells. Particles combined with the antibody (Pt-PLGA-PEG-EGFR) reported more cellular uptake with an increase in uptake over time compared to the other particles tested. Statistically significant differences were documented between Pt-PLGA-PEG-EGFR and PtNPs, demonstrating that the combination with an antibody increases cellular uptake of the particles. When comparing both sets of surface modifications, statistically significant differences were not found with cellular uptake, however, the cell viability and live/dead experiments indicate a stronger anticancer effect of Pt-PLGA-PEG-EGFR than Pt-PLGA-PEG.

## Conclusions

In this study, synthesized PtNPs were found to have a potent anticancer effect against TNBC and no toxicity for healthy cells, an improvement when compared with common chemotherapeutics drugs like cisplatin, which was toxic for both cell lines. These results are consistent with other published studies that show an anti-cancer effect with Pt NPs<sup>1,20</sup> and no toxicity in healthy cells.<sup>10,19</sup> To increase PtNPs cellular uptake, a delivery system of targeted PLGA particles were used. By using nanomulsion, encapsulation of the PtNPs was achieved with 59% of the PLGA particles containing PtNPs, and 12.5% of PtNP loading by weight. To achieve passive and active targeting of the particles, surface modifications were performed, obtaining two different sets of particles: Pt-PLGA-PEG (PEGylated) and Pt-PLGA-PEG-EGFR (conjugated with an EGFR antibody). Cell experiments were performed with both sets of particles against TNBC, showing more cell death with Pt-PLGA-PEG-EGFR than with Pt-PLGA-PEG, which confirmed the targeting of the cells by the antibody. When Pt-PLGA-PEG-EGFR particles were compared with free PtNPs a stronger anticancer effect was observed by free PtNPs, likely due to the time needed to release PtNPs from PLGA for the Pt-PLGA-PEG-EGFR particles. The internalization of Pt by the cells, however, was larger with the EGFR targeted particles, suggesting that with longer times, the anti-cancer effect will be more pronounced. This work demonstrates that PtNPs can be delivered through a targeted delivery system and have the potential to be effective cancer treatments. For future studies, *in vivo* experiments and release profiles should be performed to have a better understanding of the behavior of PtNPs.

## Author contributions

A. L. R. conducted the majority of the experiments and wrote the manuscript, E. V. A. conducted some experiments and helped

writing the manuscript and K. M. provided advice and support. The manuscript was read and corrected by all the authors.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank Sean Bannon, Ann Therese Ramirez, Suseendran Umakath, Ashish Kokkula, and Guangliang Liu for their help with cell culture, jetting nanoparticles, and NMR. We thank Dr Doherty, director of the inorganic analysis facility at Rutgers University for the ICP-MS analysis. This research has been funded by a grant from New Jersey Health Foundation (#PC 23-19).

## References

- 1 B. Şahin, A. Aygün, H. Gündüz, K. Şahin, E. Demir, S. Akocak and F. Şen, Cytotoxic Effects of Platinum Nanoparticles Obtained from Pomegranate Extract by the Green Synthesis Method on the MCF-7 Cell Line, *Colloids Surf., B*, 2018, **163**, 119–124.
- 2 A. K. Sahoo, U. Goswami, D. Dutta, S. Banerjee, A. Chattopadhyay and S. S. Ghosh, Silver Nanocluster Embedded Composite Nanoparticles for Targeted Prodrug Delivery in Cancer Theranostics, *ACS Biomater. Sci. Eng.*, 2016, **2**, 1395–1402.
- 3 A. S. D. S. Indrasekara, B. J. Paladini, D. J. Naczynski, V. Starovoytov, P. V. Moghe and L. Fabris, Dimeric Gold Nanoparticle Assemblies as Tags for SERS-Based Cancer Detection, *Adv. Healthcare Mater.*, 2013, **2**, 1370–1376.
- 4 M. Rai, A. P. Ingle, I. Gupta and A. Brandelli, Bioactivity of Noble Metal Nanoparticles Decorated with Biopolymers and Their Application in Drug Delivery, *Int. J. Pharm.*, 2015, **496**, 159–172.
- 5 A. Mulgaonkar, S. Moeendarbari, W. Silvers, G. Hassan, X. Sun, Y. Hao and W. Mao, Hollow Gold Nanoparticles as Efficient *In Vivo* Radiosensitizing Agents for Radiation Therapy of Breast Cancer, *J. Biomed. Nanotechnol.*, 2017, **13**, 566–574.
- 6 P. Jin, X. Niu, Z. Gao, X. Xue, F. Zhang, W. Cheng, C. Ren, H. Du, A. Manyande and H. Chen, Ultrafine Platinum Nanoparticles Supported on Covalent Organic Frameworks As Stable and Reusable Oxidase-Like Catalysts for Cellular Glutathione Detection, *ACS Appl. Nano Mater.*, 2021, **4**, 5834–5841.
- 7 P. Patel, V. M. Nadar, D. Umapathy, S. Manivannan, R. Venkatesan, V. A. Joseph Arokiyam, S. Pappu, P. A. Prakash, M. S. Mohamed Jabir, B. Gulyás, P. Padmanabhan, S. T. Selvan and P. Kumar, Doxorubicin-Conjugated Platinum Theranostic Nanoparticles Induce Apoptosis via Inhibition of a Cell Survival (PI3K/AKT) Signaling Pathway in Human Breast Cancer Cells, *ACS Appl. Nano Mater.*, 2021, **4**, 198–210.



- 8 H. Gehrke, J. Pelka, C. G. Hartinger, H. Blank, F. Bleimund, R. Schneider, D. Gerthsen, S. Bräse, M. Crone, M. Türk and D. Marko, Platinum Nanoparticles and Their Cellular Uptake and DNA Platination at Non-Cytotoxic Concentrations, *Arch. Toxicol.*, 2011, **85**, 799–812.
- 9 S. F. Adil, M. E. Assal, M. Khan, A. Al-Warthan, M. R. H. Siddiqui and L. M. Liz-Marzán, Biogenic Synthesis of Metallic Nanoparticles and Prospects Toward Green Chemistry, *Dalton Trans.*, 2015, **44**, 9709–9717.
- 10 A. López Ruiz, C. Bartomeu García, S. Navarro Gallón and T. J. Webster, Novel Silver-Platinum Nanoparticles for Anti-cancer and Antimicrobial Applications, *Int. J. Nanomed.*, 2020, **15**, 169–179.
- 11 H. Mohammadi, A. Abedi, A. Akbarzadeh, M. J. Mokhtari, H. E. Shahmabadi, M. R. Mehrabi, S. Javadian and M. Chiani, Evaluation of Synthesized Platinum Nanoparticles on the MCF-7 and HepG-2 Cancer Cell Lines, *Int. Nano Lett.*, 2013, **3**, 28.
- 12 J. Rajput, J. R. Moss, A. T. Hutton, D. T. Hendricks, C. E. Arendse and C. Imrie, Synthesis, Characterization and Cytotoxicity of Some Palladium(II), Platinum(II), Rhodium(I) and Iridium(I) Complexes of Ferrocenylpyridine and Related Ligands. Crystal and Molecular Structure of Trans-Dichlorobis(3-Ferrocenylpyridine)Palladium(II), *J. Organomet. Chem.*, 2004, **689**, 1553–1568.
- 13 Y. Bendale, V. Bendale, S. Paul and S. S. Bhattacharyya, Green Synthesis, Characterization and Anticancer Potential of Platinum Nanoparticles Bioplatin, *Zhongxiyi Jiehe Xuebao*, 2012, **10**, 681–692.
- 14 Y. Bendale, V. Bendale and S. Paul, Evaluation of Cytotoxic Activity of Platinum Nanoparticles against Normal and Cancer Cells and Its Anticancer Potential through Induction of Apoptosis, *Integr. Med. Res.*, 2017, **6**, 141–148.
- 15 M. Yamada, M. Foote and T. W. Prow, Therapeutic Gold, Silver, and Platinum Nanoparticles, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2015, **7**, 428–445.
- 16 J. Gao, G. Liang, B. Zhang, Y. Kuang, X. Zhang and B. Xu, FePt@CoS<sub>2</sub> Yolk-Shell Nanocrystals as a Potent Agent to Kill HeLa Cells, *J. Am. Chem. Soc.*, 2007, **129**, 1428–1433.
- 17 D. Pedone, M. Moglianetti, E. De Luca, G. Bardi and P. P. Pompa, Platinum Nanoparticles in Nanobiomedicine, *Chem. Soc. Rev.*, 2017, **46**, 4951–4975.
- 18 P. G. González-Larraz, T. M. López-Goerne, F. J. Padilla-Godínez, M. A. González-López, A. Hamdan-Partida and E. Gómez, IC<sub>50</sub> Evaluation of Platinum Nanocatalysts for Cancer Treatment in Fibroblast, HeLa, and DU-145 Cell Lines, *ACS Omega*, 2020, **5**, 25381–25389.
- 19 P. V. Asharani, Y. Lianwu, Z. Gong and S. Valiyaveetil, Comparison of the Toxicity of Silver, Gold and Platinum Nanoparticles in Developing Zebrafish Embryos, *Nanotoxicology*, 2011, **5**, 43–54.
- 20 C. X. Lin, J. L. Gu and J. M. Cao, The Acute Toxic Effects of Platinum Nanoparticles on Ion Channels, Transmembrane Potentials of Cardiomyocytes in Vitro and Heart Rhythm in Vivo in Mice, *Int. J. Nanomed.*, 2019, **14**, 5595–5609.
- 21 Y. Li, K. H. Yun, H. Lee, S. H. Goh, Y. G. Suh and Y. Choi, Porous platinum nanoparticles high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo, *Bio Mater.*, 2019, **197**, 12–19.
- 22 SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED). [https://www.accessdata.fda.gov/cdrh\\_docs/pdf4/P040046b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040046b.pdf), (accessed September 6, 2018).
- 23 S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad and S. J. Lippard, Targeted Delivery of Cisplatin to Prostate Cancer Cells by Aptamer Functionalized Pt(IV) Prodrug-PLGA-PEG Nanoparticles, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 17356–17361.
- 24 A. Kumari, S. K. Yadav and S. C. Yadav, Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems, *Colloids Surf., B*, 2010, **75**, 1–18.
- 25 T. Safra, F. Muggia, S. Jeffers, D. D. Tsao-Wei, S. Groshen, O. Lyass, R. Henderson, G. Berry and A. Gabizon, Pegylated Liposomal Doxorubicin (Doxil): Reduced Clinical Cardio-toxicity in Patients Reaching or Exceeding Cumulative Doses of 500 Mg/M<sup>2</sup>, *Ann. Oncol.*, 2000, **11**, 1029–1033.
- 26 M. L. Hans and A. M. Lowman, Biodegradable Nanoparticles for Drug Delivery and Targeting, *Curr. Opin. Solid State Mater. Sci.*, 2002, **6**, 319–327.
- 27 J. Keyvan Rad, Z. Alinejad, S. Khoei and A. R. Mahdavian, Controlled Release and Photothermal Behavior of Multi-purpose Nanocomposite Particles Containing Encapsulated Gold-Decorated Magnetite and 5-FU in Poly(lactide-co-glycolide), *ACS Biomater. Sci. Eng.*, 2019, **5**, 4425–4434.
- 28 F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton and V. Préat, PLGA-Based Nanoparticles: An Overview of Biomedical Applications, *J. Controlled Release*, 2012, **161**, 505–522.
- 29 H. Lee, C.-H. Ahn and T. G. Park, Poly[lactic-co-(glycolic acid)]-Grafted Hyaluronic Acid Copolymer Micelle Nanoparticles for Target-Specific Delivery of Doxorubicin, *Macromol. Biosci.*, 2009, **9**, 336–342.
- 30 M. M. Stevanović, S. D. Škapin, I. Bračko, M. Milenković, J. Petković, M. Filipič and D. P. Uskoković, Poly(lactide-co-glycolide)/Silver Nanoparticles: Synthesis, Characterization, Antimicrobial Activity, Cytotoxicity Assessment and ROS-Inducing Potential, *Polymer*, 2012, **53**, 2818–2828.
- 31 J. C. Ramirez, S. E. Flores-Villaseñor, E. Vargas-Reyes, J. Herrera-Ordóñez, S. Torres-Rincón and R. D. Peralta-Rodríguez, Preparation of PDLLA and PLGA Nanoparticles Stabilized with PVA and a PVA-SDS Mixture: Studies on Particle Size, Degradation and Drug Release, *J. Drug Delivery Sci. Technol.*, 2020, **60**, 101907.
- 32 J. Plch, K. Venclikova, O. Janouskova, J. Hrabeta, T. Eckschlager, K. Kopeckova, Z. Hampejsova, Z. Bosakova, J. Sirc and R. Hobzova, Paclitaxel-Loaded Polylactide/Polyethylene Glycol Fibers with Long-Term Antitumor Activity as a Potential Drug Carrier for Local Chemotherapy, *Macromol. Biosci.*, 2018, **18**, 1800011.
- 33 J. Patel, J. Amrutiya, P. Bhatt, A. Javia, M. Jain and A. Misra, Targeted Delivery of Monoclonal Antibody Conjugated Docetaxel Loaded PLGA Nanoparticles into EGFR Overexpressed Lung Tumour Cells, *J. Microencapsulation*, 2018, **35**, 204–217.



- 34 A. Saneja, D. Arora, R. Kumar, R. D. Dubey, A. K. Panda and P. N. Gupta, CD44 Targeted PLGA Nanomedicines for Cancer Chemotherapy, *Eur. J. Pharm. Sci.*, 2018, **121**, 47–58.
- 35 B. B. S. Cerqueira, A. Lasham, A. N. Shelling and R. Al-Kassas, Development of Biodegradable PLGA Nanoparticles Surface Engineered with Hyaluronic Acid for Targeted Delivery of Paclitaxel to Triple Negative Breast Cancer Cells, *Mater. Sci. Eng., C*, 2017, **76**, 593–600.
- 36 S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk, D. Fischer, K. Kiouptsi, C. Reinhardt, K. Landfester, H. Schild, M. Maskos, S. K. Knauer and R. H. Stauber, Rapid Formation of Plasma Protein Corona Critically Affects Nanoparticle Pathophysiology, *Nat. Nanotechnol.*, 2013, **8**, 772–781.
- 37 J. S. Suk, Q. Xu, N. Kim, J. Hanes and L. M. Ensign, PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery, *Adv. Drug Delivery Rev.*, 2016, **99**, 28–51.
- 38 R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin and R. Langer, Biodegradable Long-Circulating Polymeric Nanospheres, *Science*, 1994, **263**, 1600–1603.
- 39 M. E. Davis, Z. Chen and D. M. Shin, Nanoparticles Therapeutics: An Emerging Treatment Modality for Cancer, *Nat. Rev. Drug Discovery*, 2008, **7**, 771–782.
- 40 P. J. Kennedy, F. Sousa, D. Ferreira, C. Pereira, M. Nestor, C. Oliveira, P. L. Granja and B. Sarmento, Fab-Conjugated PLGA Nanoparticles Effectively Target Cancer Cells Expressing Human CD44v6, *Acta Biomater.*, 2018, **81**, 208–218.
- 41 B. Bahrami, M. Hojjat-Farsangi, H. Mohammadi, E. Anvari, G. Ghalamfarsa, M. Yousefi and F. Jadidi-Niaragh, Nanoparticles and Targeted Drug Delivery in Cancer Therapy, *Immunol. Lett.*, 2017, **190**, 64–83.
- 42 S. Cleator, W. Heller and R. C. Coombes, Triple-Negative Breast Cancer: Therapeutic Options, *Lancet Oncol.*, 2007, **8**, 235–244.
- 43 J. Collignon, L. Lousberg, H. Schroeder and G. Jerusalem, Triple-Negative Breast Cancer: Treatment Challenges and Solutions, *Breast Cancer: Targets Ther.*, 2016, **8**, 93–107.
- 44 J. J. Arroyo-Crespo, A. Armiñán, D. Charbonnier, C. Deladriere, M. Palomino-Schätzlein, R. Lamas-Domingo, J. Forteza, A. Pineda-Lucena and M. J. Vicent, Characterization of Triple-Negative Breast Cancer Preclinical Models Provides Functional Evidence of Metastatic Progression, *Int. J. Cancer*, 2019, **145**, 2267–2281.
- 45 G. Bianchini, J. M. Balko, I. A. Mayer, M. E. Sanders and L. Gianni, Triple-negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease, *Nat. Rev. Clin. Oncol.*, 2016, **13**, 674–690.
- 46 F. Fay and C. J. Scott, Antibody-Targeted Nanoparticles for Cancer Therapy, *Immunotherapy*, 2011, **3**, 381–394.
- 47 J. Gu, L. Yin, J. Wu, N. Zhang, T. Huang, K. Ding, H. Cao, L. Xu and X. He, Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway, *Biochem. Res. Int.*, 2016, **2016**, 7016907.
- 48 R. V. Kutty and S. S. Feng, Cetuximab Conjugated Vitamin E TPGS Micelles for Targeted Delivery of Docetaxel for Treatment of Triple Negative Breast Cancers, *Biomaterials*, 2013, **34**, 10160–10171.
- 49 W. S. Liao, Y. Ho, Y. W. Lin, E. Naveen Raj, K. K. Liu, C. Chen, X. Z. Zhou, K. P. Lu and J. I. Chao, Targeting EGFR of Triple-Negative Breast Cancer Enhances the Therapeutic Efficacy of Paclitaxel- and Cetuximab-Conjugated Nanodiamond Nanocomposite, *Acta Biomater.*, 2019, **86**, 395–405.
- 50 K. Shim, J. Kim, Y.-U. Heo, B. Jiang, C. Li, M. Shahabuddin, K. C.-W. Wu, M. S. A. Hossain, Y. Yamauchi and J. H. Kim, Synthesis and Cytotoxicity of Dendritic Platinum Nanoparticles with HEK-293 Cells, *Chem. – Asian J.*, 2017, **12**, 21–26.
- 51 S. Fatima, Z. Iqbal, A. K. Panda, M. Samim, S. Talegaonkar and F. J. Ahmad, Polymeric Nanoparticles as a Platform for Permeability Enhancement of Class III Drug Amikacin, *Colloids Surf., B*, 2018, **169**, 206–213.
- 52 E. Porcel, S. Liehn, H. Remita, N. Usami, K. Kobayashi, Y. Furusawa, C. Le Sech and S. Lacombe, Platinum Nanoparticles: A Promising Material for Future Cancer Therapy?, *Nanotechnology*, 2010, **21**, 085103.
- 53 A. Borowik, R. Banasiuk, N. Derewonko, M. Rychlowski, M. Krychowiak-Masnicka, D. Wyrzykowski, M. Ziabka, A. Woziwodzka, A. Krolicka and J. Piosik, Interactions of newly synthesized platinum nanoparticles with ICR-191 and their potential application, *Sci. Rep.*, 2019, **9**, 4987.
- 54 M. Moglianetti, E. De Luca, D. Pedone, R. Marotta, T. Catelani, B. Sartori, H. Amenitsch, S. F. Retta and P. P. Pompa, Platinum nanozymes recover cellular ROS homeostasis in an oxidative stress-mediated disease model, *Nanoscale*, 2016, **8**, 3739–3752.
- 55 X. Teng, X. Liang, S. Maksimuk and H. Yang, Synthesis of Porous Platinum Nanoparticles, *Small*, 2006, **2**, 249–253.
- 56 S. Gurunathan, M. Jeyaraj, M.-H. Kang and J.-H. Kim, Graphene Oxide-Platinum Nanoparticle Nanocomposites: A Suitable Biocompatible Therapeutic Agent for Prostate Cancer, *Polymers*, 2019, **11**, 733.
- 57 A. Sharma, A. K. Goyal and G. Rath, Recent Advances in Metal Nanoparticles in Cancer Therapy, *J. Drug Targeting*, 2018, **8**, 617–632.
- 58 J. Zhuang, C.-H. Kuo, L.-Y. Chou, D.-Y. Liu, E. Weerapana and C.-K. Tsung, Optimized Metal-Organic-Framework Nanospheres for Drug Delivery: Evaluation of Small-Molecule Encapsulation, *ACS Nano*, 2014, **8**, 2812–2819.
- 59 S. Sharma, A. Parmar, S. Kori and R. Sandhir, PLGA-Based Nanoparticles: A New Paradigm in Biomedical Applications, *TrAC, Trends Anal. Chem.*, 2016, **80**, 30–40.
- 60 G. Wang and H. Uludag, Recent Developments in Nanoparticle-Based Drug Delivery and Targeting Systems with Emphasis on Protein-Based Nanoparticles, *Expert Opin. Drug Delivery*, 2008, **5**, 499–515.
- 61 M. Iqbal, N. Zafar, H. Fessi and A. Elaissari, Double Emulsion Solvent Evaporation Techniques Used for Drug Encapsulation, *Int. J. Pharm.*, 2015, **496**, 173–190.
- 62 P. Dana, S. Bunthot, K. Suktham, S. Surassmo, T. Yata, K. Namdee, W. Yingmema, T. Yimsoo, U. R. Ruktanonchai, S. Sathornsumetee and N. Saengkrit, Active targeting



- liposome-PLGA composite for cisplatin delivery against cervical cancer, *Colloids Surf., B*, 2020, **196**, 111270.
- 63 E. C. Gryparis, M. Hatzia Apostolou, E. Papadimitriou and K. Avgoustakis, Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells, *Eur. J. Pharm. Biopharm.*, 2007, **67**, 1–8.
  - 64 N. Bertrand, P. Grenier, M. Mahmoudi, E. M. Lima, E. A. Appel, F. Dormont, J. M. Lim, R. Karnik, R. Langer and O. C. Farokhzad, Mechanistic Understanding of in Vivo Protein Corona Formation on Polymeric Nanoparticles and Impact on Pharmacokinetics, *Nat. Commun.*, 2017, **8**, 777.
  - 65 L. Tang, X. Yang, Q. Yin, K. Cai, H. Wang, I. Chaudhury, C. Yao, Q. Zhou, M. Kwon, J. A. A. Hartman, I. T. Dobrucki, L. W. Dobrucki, L. B. Borst, S. Lezmi, W. G. Helferich, A. L. Ferguson, T. M. Fan and J. Cheng, Investigating the optimal size of anticancer nanomedicine, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 15344–15349.
  - 66 P. Foroozandeh and A. A. Aziz, Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles, *Nanoscale Res. Lett.*, 2018, **13**, 339.

